CoCensys, Inc. announces offering of common stock.IRVINE, Calif.--(BUSINESS WIRE)--Dec. 26, 1995--CoCensys, Inc. (Nasdaq: COCN COCN Certified Ostomy Care Nurse ) today announced that it has filed a registration statement with the Securities and Exchange Commission with respect to a proposed offering of 2.0 million newly issued shares of Common Stock to select institutional investors. The placement agent for the offering is Hambrecht & Quist LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . CoCensys is a biopharmaceutical company that discovers, develops and markets products to treat neurological and psychiatric disorders. The Company's product development programs focus on two novel, proprietary classes of compounds: Epalons, to treat epilepsy, anxiety and sleep disorders Sleep Disorders Definition Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep. ; and excitatory ex·ci·ta·tive or ex·ci·ta·to·ry adj. Causing or tending to cause excitation. Adj. 1. excitatory - (of drugs e.g. amino acid (EAA EAA Experimental Aircraft Association EAA European Aluminium Association (Brussels, Belgium) EAA European Acoustics Association EAA Export Administration Act EAA Everglades Agricultural Area EAA European Association of Archaeologists ) antagonists, to treat stroke and head injury. Through its marketing alliances with Ciba Pharmaceuticals and Parke-Davis, CoCensys also markets several CNS See Continuous net settlement. CNS See continuous net settlement (CNS). products, including Anafranil(R) for the treatment of obsessive compulsive disorder Obsessive compulsive disorder (OCD) Disorder characterized by persistent, intrusive, and senseless thoughts (obsessions) or compulsions to perform repetitive behaviors that interfere with normal functioning. Mentioned in: Tourette Syndrome , Tofranil(R) and Tofranil-PM(R) for depression and Cognex(R) for the treatment of Alzheimer's disease. A preliminary prospectus relating to these securities may be obtained from Hambrecht & Quist LLC, One Bush Street, 18th Floor, San Francisco, CA 94104, or 230 Park Avenue, New York, NY, 10169, Attn.: Prospectus Department. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. CONTACT: Joseph F. Fojtasek Clarence Swearngan, Jr. (investors) Chief Financial Officer Karen Bergman (media) CoCensys, Inc. Burns McClellan, Inc. 714-753-6100 212-505-1919 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion